EP 215: Vectorized RNAi and the next frontier of gene silencing with Rachel Salzman of Armatus Bio

<p><strong>Summary: </strong></p><p>This week on The Genetics Podcast, Patrick is joined by Dr. Rachel Salzman, CEO of Armatus Bio. They discuss the promise of vectorized RNAi for autosomal dominant diseases, the key scientific and clinical hurdles in gene therapy, and Rachel’s lessons from two decades in the field.</p><p><strong>Show Notes: </strong></p><p><strong>0:00 </strong>Intro to The Genetics Podcast</p><p><strong>01:00</strong> Welcome to Rachel</p><p><strong>01:35</strong> Background of Armatus Bio and the mechanism behind its vectorized RNAi platform</p><p><strong>05:31</strong> Advantages of vectorized RNAi over conventional RNAi approaches</p><p><strong>08:07 </strong>How microRNAs work and how engineered versions enable highly specific gene silencing</p><p><strong>10:28 </strong>Current preclinical progress at Armatus and next steps toward first-in-human trials</p><p><strong>14:06 </strong>Lessons on making smart risk decisions in rare disease drug development</p><p><stro...